1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1066

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Glycopyrronium bromide
DRUG: Placebo to glycopyrronium bromide
DRUG: Tiotropium

Sponsor

Novartis